Xu, Ke
Li, Boyang http://orcid.org/0000-0003-2808-9986
McGinnis, Kathleen A.
Vickers-Smith, Rachel
Dao, Cecilia
Sun, Ning
Kember, Rachel L.
Zhou, Hang http://orcid.org/0000-0002-7694-6391
Becker, William C.
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Zhao, Hongyu http://orcid.org/0000-0003-1195-9607
Justice, Amy C. http://orcid.org/0000-0003-0139-5502
,
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1I01BX003341)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA038632, R01DA047063, R01DA047820)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
Article History
Received: 5 April 2019
Accepted: 20 August 2020
First Online: 20 October 2020
Competing interests
: H.R.K. is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. H.R.K. and J.G. are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. The other authors have no competing interests to declare.